XRCC5 and cancer: Targeting the Ku70 and Ku80 proteins to disrupt their association has been proposed for cancer treatment (45, 46), with our results suggesting that MILIP represents an alternative yet potent avenue for inhibiting the Ku70–Ku80 interaction.